Natco Pharma Ltd - 524816 - Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- M ADINARAYANADesignation :- Company Secretary and Compliance Officer Natco Pharma gets EIR from USFDA for Hyderabad facility
The plant was inspected during the period August 5-9, 2019 Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO RECEIVES ESTABLISHMENT INSPECTION REPORT FOR MEKAGUDA's ACTIVE PHARMACEUTICAL INGREDIENT FACILITY Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 1,25,215 Equity shares of Rs.2/- each under NATCO Employee Stock Option Scheme(NATSOP2015) Natco Pharma lines up 20 `Para IV' products
Para IV products mean, "the first company which submits a completed ANDA (Abbreviated New Drug Application) is given marketing exclusivity for 180 days." NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the Quarter ended June 30, 2019 Natco Pharma Ltd - 524816 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Natco Pharma Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Natco Pharma Ltd - 524816 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Outcome of 36th Annual General Meeting & Voting Results NATCO PHARMA LTD. - 524816 - Proceedings Of 36Th Annual General Meeting
Proceedings of 36th Annual General Meeting